What it is

A water-soluble polysaccharide fibre, engineered to a low molecular weight so it works as a clean prebiotic substrate without the bulk of conventional fibres. Its job is direct: support the gut's short-chain fatty acid producers — the bacteria that turn fibre into butyrate and propionate, central signals in gut, metabolic, and gut-brain health.

TRI-04 water-soluble prebiotic fibre butyrate propionate other short-chain fatty acids what they make the same gut community → fed: the ones that can use it
  • butyrate producers
  • propionate producers
  • other groups with metabolic roles
  • the rest of the community
Mechanism — no numbers shown TRI-04 feeds the organisms across the community that can use it. Butyrate producers are part of that, and so are propionate producers and other groups with metabolic roles. We are still working through how much each group moves, so no figures are shown here.

Why it's different

  • A direct, well-understood mechanism. A polysaccharide fibre that feeds the gut's short-chain fatty acid producers as a substrate — no receptor pharmacology, no precursor conversion step to argue about.
  • Formulator-friendly economics at scale. Engineered for a favourable cost-of-goods trajectory as volume grows, so it works in both premium and mass formats.
  • Low-MW and water-soluble. Works without the gram-scale bulk and sensory load that keeps conventional fibres out of premium compact formats.
  • A metabolic-health claim path. Short-chain fatty acid signalling from the gut is well-supported biology; TRI-04 is pursuing a standalone metabolic-health claim ("supports healthy glucose response" / "supports satiety") through clinical work. A claim path under study.
  • A lean regulatory route. Self-Affirmed GRAS via History-of-Safe-Consumption read-across — a faster, leaner dossier than a full GRAS notification.

Where it fits

The closest reference point in market is the kiwi-derived butyrate-modulator category (e.g. Livaux), which sells a butyrate story at premium-extract economics. TRI-04 differs on mechanism class (a low-MW fibre, not a fruit polyphenol), on cost trajectory at scale, and on its standalone metabolic-health claim path. We frame the category gap, not any competitor's shortcomings.

What you can claim

  • At launch — gut health. Gut-health structure-function (supporting butyrate production), on the mechanism + Self-Affirmed GRAS.
  • With clinical readout — substantiated gut health. Planned clinical work substantiates the gut-health claim.
  • The destination — metabolic health. A standalone metabolic-health claim gated on a dedicated clinical readout. Under study.

Regulatory & supply

  • Pathway: US Self-Affirmed GRAS via HoSC read-across (lean dossier). First revenue targeted Q2 2027 — the first Trilliome active to reach market.
  • Dose scenarios: suited to both a premium / capsule format and a mass / RTD-and-powder format. Dose detail is shared with partners under confidentiality.
  • You receive: CoA per batch, specification sheet, TDS, allergen statement.
  • Process: produced from an upcycled agricultural side-stream via a food-grade process. (Quality & manufacturing detail on /science/quality.)

Formats

Capsules · RTD beverages · fortified powders · fibre blends · functional foods.

Request specs & samples See the evidence
What is TRI-04?
A low-molecular-weight, water-soluble prebiotic fibre that supports the gut's short-chain fatty acid producers — the butyrate producers and the propionate producers alongside them.
How is it different from inulin or GOS?
Low molecular weight and water-soluble, so it works without the gram-scale bulk and sensory load of conventional fibres, with a targeted mechanism that supports the gut's short-chain fatty acid producers.
Can it carry a metabolic-health claim?
That's a claim path under study via clinical work. At launch it carries gut-health structure-function claims.
What's the regulatory status?
Self-Affirmed GRAS via HoSC read-across; first revenue targeted Q2 2027, ahead of TRI-01.